SBIR-STTR Award

Multiplexed High-Content Assay for Toxicity Profiling Using Live iPSC-Derived Cardiomyocyte Lines with Lineage-Specific Barcoding
Award last edited on: 1/7/2020

Sponsored Program
SBIR
Awarding Agency
NIH : NCATS
Total Award Amount
$1,999,946
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Mary Ludlam Cole

Company Information

Cairn Biosciences Inc

455 Mission Bay Boulevard South Suite 145
San Francisco, CA 94158
   (415) 269-2956
   info@cairnbio.com
   www.cairnbio.com
Location: Single
Congr. District: 12
County: San Francisco

Phase I

Contract Number: N/A
Start Date: 8/15/2018    Completed: 7/31/2020
Phase I year
2018
Phase I Amount
$1
Human induced pluripotent stem cells (hiPSCs) are poised to transform toxicological evaluation, however new approaches to enable their functional and structural profiling are needed to improve the utility of hiPSC -based models for predictive and mechanistic toxicology screening. This need is addressed by our project?s Specific Aims that encompass (1) development of a novel platform for generation of hiPSC-derived reporter cells; (2) generation of a panel of multicolor hiPSC-derived cardiomyocytes (hiPSC-CMs) with stable lineage specific fluorescent reporters; and (3) implementation and validation of a pilot machine learning-enabled predictive cardiotoxicity screen using these tools. The proposed tools are configured to be extensible to other toxicology- relevant pathways and phenotypes making it uniquely positioned to capitalize on the growing commercial need for high-throughput predictive toxicology assays. The project deliverables benefit public health by improving the ability to rapidly identify liabilities in specific cardiomyocyte lineage types, thus reducing the time and cost to pinpoint cardiotoxicity of pharmaceutical and environmental chemicals.

Phase II

Contract Number: 2R44TR002572-02
Start Date: 8/15/2018    Completed: 7/31/2020
Phase II year
2018
(last award dollars: 2019)
Phase II Amount
$1,999,945

Human induced pluripotent stem cells (hiPSCs) are poised to transform toxicological evaluation, however new approaches to enable their functional and structural profiling are needed to improve the utility of hiPSC -based models for predictive and mechanistic toxicology screening. This need is addressed by our project?s Specific Aims that encompass (1) development of a novel platform for generation of hiPSC-derived reporter cells; (2) generation of a panel of multicolor hiPSC-derived cardiomyocytes (hiPSC-CMs) with stable lineage specific fluorescent reporters; and (3) implementation and validation of a pilot machine learning-enabled predictive cardiotoxicity screen using these tools. The proposed tools are configured to be extensible to other toxicology- relevant pathways and phenotypes making it uniquely positioned to capitalize on the growing commercial need for high-throughput predictive toxicology assays. The project deliverables benefit public health by improving the ability to rapidly identify liabilities in specific cardiomyocyte lineage types, thus reducing the time and cost to pinpoint cardiotoxicity of pharmaceutical and environmental chemicals.